1. Home
  2. INTZ vs RNTX Comparison

INTZ vs RNTX Comparison

Compare INTZ & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intrusion Inc.

INTZ

Intrusion Inc.

HOLD

Current Price

$1.31

Market Cap

30.0M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.36

Market Cap

35.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTZ
RNTX
Founded
1983
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.0M
35.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
INTZ
RNTX
Price
$1.31
$1.36
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$7.25
$10.00
AVG Volume (30 Days)
129.9K
209.2K
Earning Date
02-26-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,290,000.00
N/A
Revenue This Year
$35.44
N/A
Revenue Next Year
$23.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
33.49
N/A
52 Week Low
$0.71
$1.02
52 Week High
$2.64
$3.50

Technical Indicators

Market Signals
Indicator
INTZ
RNTX
Relative Strength Index (RSI) 47.78 60.68
Support Level $1.21 $1.12
Resistance Level $1.52 $1.25
Average True Range (ATR) 0.10 0.09
MACD 0.01 0.03
Stochastic Oscillator 30.30 100.00

Price Performance

Historical Comparison
INTZ
RNTX

About INTZ Intrusion Inc.

Intrusion Inc is a cybersecurity company based in Plano, Texas. The group offers customers to access its threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol (IP) addresses. The company's product consists of On-Premise Network Protection, Cyber Threat Consulting, Cloud Network Security, and Endpoint Protection. Its solutions are INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. Its end-user customers include the U.S. federal government, state and local government entities, large and diversified conglomerates, and manufacturing entities.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: